Study Evaluating PSI-697 in Patients With Scleritis
To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
|Official Title:||An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00367692
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|